Evgen Pharma Appoints Chief Medical Officer
News Jan 05, 2016
Evgen Pharma plc has announced the appointment of Dr Hamina J Patel MB BCh MSc MRCPI as Chief Medical Officer.
Dr Patel is a pharmaceutical executive with more than 15 years’ industry experience, leading global cross functional teams in the development and commercialization of drugs primarily within the field of oncology.
Dr Patel was previously Director of Drug Development, Oncology, at Johnson and Johnson, where she helped to build a broad and differentiated portfolio of indications for the cancer drug VELCADE® and was instrumental in the success of a new indication (the second-line treatment of mantle cell lymphoma) based on a Phase II clinical study in more than 35 countries. She received numerous awards for her contribution to the Oncology group at Johnson and Johnson, including a Standard of Leadership award.
In addition to her small molecule expertise, Dr Patel has worked extensively in the development of biopharmaceuticals at Celltech and at Chugai.
Dr Patel qualified as a physician in 1990 and worked for almost ten years in hospitals around the UK before moving into the pharmaceutical industry.
Dr Stephen Franklin, Evgen Pharma’s CEO, commented: “We are delighted to announce the appointment of Dr Hamina Patel as Evgen’s Chief Medical Officer. Hamina has an impressive track record at global pharmaceutical companies and a breadth of relevant clinical experience. Her appointment strengthens the core team at Evgen and will be of great value in the delivery of our upcoming Phase II clinical trials in metastatic breast cancer and in subarachnoid haemorrhage, both of which are on track to begin this year.”
Five Sub-types of the Brain Cancer Glioma IdentifiedNews
There are five distinct molecular sub-types of the brain cancer glioma, according to findings from the largest ever genetic study of its kind of the cancer.READ MORE
Compound Selectively Kills Liver Cancer Stem CellsNews
Acyclic retinoid, an artificial compound derived from vitamin A, has been found to prevent the recurrence of hepatocellular carcinoma (HCC), the most common form of liver cancer.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018